Detalhe da pesquisa
1.
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
N Engl J Med
; 378(26): 2475-2485, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29782224
2.
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
N Engl J Med
; 378(26): 2486-2496, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29782217
3.
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Gastroenterology
; 158(1): 111-122.e10, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31593702
4.
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
Clin Exp Allergy
; 51(7): 915-931, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34037993
5.
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Lancet
; 394(10209): 1638-1650, 2019 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31543428
6.
Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Allergy
; 75(1): 148-157, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31306495
7.
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.
Ann Allergy Asthma Immunol
; 125(5): 565-576.e1, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474156
8.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
J Am Acad Dermatol
; 82(2): 377-388, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31374300
9.
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
Rhinology
; 58(1): 10-17, 2020 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31671432
10.
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
J Allergy Clin Immunol
; 143(1): 155-172, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30194992
11.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
N Engl J Med
; 375(24): 2335-2348, 2016 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27690741
12.
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
Allergy
; 74(4): 743-752, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30488542
13.
Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma.
Ann Allergy Asthma Immunol
; 122(1): 41-49.e2, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30138668
14.
Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
J Am Acad Dermatol
; 80(1): 158-167.e1, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30092324
15.
Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Acta Derm Venereol
; 99(10): 851-857, 2019 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31099402
16.
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.
J Allergy Clin Immunol
; 142(1): 171-177.e1, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29355679
17.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Lancet
; 389(10086): 2287-2303, 2017 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28478972
18.
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting ß2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Lancet
; 388(10039): 31-44, 2016 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27130691
19.
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Lancet
; 387(10013): 40-52, 2016 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26454361
20.
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
N Engl J Med
; 371(2): 130-9, 2014 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25006719